- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03380039
Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma
Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is designed to determine the safety, tolerability and engraftment potential of anti-BCMA lentivirus-transduced autologous T cells in patients with refractory or relapsed multiple myeloma.
Primary objectives:
- Determine the safety and tolerability of CAR-BCMA T cells (autologous T cells transduced with chimeric antigen receptors recognizing BCMA) in patients with refractory or relapsed multiple myeloma.
- Observe the cytokinetics of CAR-BCMA T cells.
Secondary objectives:
- Observe the anti-tumor response of CAR-BCMA T cells to refractory or relapsed multiple myeloma (evaluated by diagnostic criteria International Myeloma Working Group (IMWG2014 version) as CR, sCR, ICR, MCR or VGPR).
- Make an evaluation on the distribution and in vivo survival of CAR-BCMA T cells in peripheral blood, lymph node, and bone marrow.
- Observe the immunogenicity of CAR-BCMA T cells, and determine if there is anti-BCMA scFv cellular immune response and anti-BCMA scFv humoral immune response.
- Observe the changes of cell subsets of CAR-BCMA T cells against T cells (Tcm, central memory T lymphocytes; Tem, effector memory T lymphocytes; Treg, regulatory T lymphocytes).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200092
- Xin Hua Hospital of Shanghai Jiao Tong University of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged between 18 ~ 70 with relapsed or refractory multiple myeloma.
- Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination.
Patients with relapsed or refractory multiple myeloma who meet the following conditions:
- 1) Curative efficacy is little or disease progressed after 2 courses of standard treatment regimen;
- 2) Disease relapsed after chemotherapy or HSCT. Curative efficacy is little or disease progressed after 2 courses of original treatment regimen;
- 3) More than 60 days between last treatment and disease progression;
- 4) Autologous or allogeneic SCT is not available at present, or patient refuses to receive SCT;
- 5) Disease progression is defined as per "Chinese Guidelines for Diagnosis and Treatment of Multiple Myeloma (Revision in 2015)". At least one of the following conditions should be met:
- - i. Serum M-protein increases ≥ 25% (absolute increase should be ≥ 5 g/L). If serum M protein is ≥ 50 g/L at baseline, increase of serum M protein can be ≥ 10 g/L;
- - ii. Urine M-protein increases ≥ 25% (absolute increase should be ≥ 200 mg/24 h);
- - iii. If the serum and urine M-protein are not detectable, a ≥ 25% increase in the difference between involved and uninvolved FLC levels is required (absolute increase should be ≥ 100 mg/L);
- - iv. Bone marrow plasma cell percentage increases ≥ 25% (absolute increase should be ≥ 10%);
- - v. Size of existing bone lesions or soft tissue plasmacytomas increases by ≥ 25%, or development of new lytic bone lesions or soft tissue plasmacytomas;
- - vi. Development of hypercalcemia that can be attributed to plasma cell proliferative disorder (corrected calcium is > 2.8 mmol/L or 11.5 mg/dL);
- - vii. Disease progression must be confirmed by 2 sequential assessments.
- Expected survival > 12 weeks.
Disease is measurable, and at least one of the following conditions should be satisfied:
- 1) Serum M-protein is ≥ 10 g/L;
- 2) 24-hour urine M-protein is ≥ 200 mg;
- 3) Serum FLC is ≥ 5 mg/dL;
- 4) Plasmacytomas that can be measured or evaluated by imaging;
- 5) Bone marrow plasma cell percentage is ≥ 20%.
- ECOG scores 0 - 1.
- Adequate venous access for apheresis and venous blood sampling, and no other contraindications for leukapheresis.
- WBC ≥ 1.5×10^9/L, PLT ≥ 45×10^9/L;
- Serum creatinine ≤ 1.5 ULN.
- ALT ≤ 2.5 ULN, AST ≤ 2.5 ULN. The above lab results should not include those obtained from continuous supportive treatment that is ongoing.
Exclusion Criteria:
Patients with any of the following conditions are not eligible for this study.
- Transduction of target lymphocytes < 10%, expansion in response to αCD3/CD28 costimulation < 5-fold.
- Pregnant or lactating women.
- HIV positive, or HCV positive
- Uncontrolled active infection, including active tuberculosis and HBV DNA copies ≥ 1×10^3 copies/mL.
- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
- Allergic to immunotherapies and related drugs.
- Patients with heart disease for which treatment is needed or with poorly controlled hypertension.
- Hyponatremia: serum sodium level < 125 mmol/L.
- Baseline serum potassium < 3.5 mmol/L (taking potassium supplements before participating in the study to raise potassium level is acceptable).
- Previous treatment with chemoradiotherapy, immunotherapy and tumor-targeting drug conducted 2 weeks prior to participation in this study or blood collection.
- Patients have undertaken immunosuppressor for graft-versus-host disease (GVHD) within 4 weeks before participation in this study or blood collection, or the patient is diagnosed with acute or chronic GVHD.
- Other severe disease that may restrain patients from participating in this study (e.g. diabetes, severe cardiac dysfunction, myocardial infarction or unstable arrhythmias or unstable angina in recent 6 months, gastric ulcer, active autoimmune disease, etc.).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CAR-BCMA T cells
In this study, autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells) are used to treat patients with refractory or relapsed multiple myeloma. Route of administration: Intravenous injection. Lymphodepletion conditioning: Lymphodepletion will be conducted several days prior to CAR-BCMA T cells infusion. A combination of fludarabine and cyclophosphamide will be used for lymphodepletion. |
Single dose of CAR-BCMA T cells will be infused, and classic "3+3" dose escalation will be applied.
Other Names:
Fludarabine is used for lymphodepletion.
Cyclophosphamide is used for lymphodepletion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with CAR-BCMA T cell therapy-related adverse events as assessed by CTCAE v4.03
Time Frame: 24 weeks
|
Number of participants with study related adverse events which are defined as laboratory toxicities and clinical events that are possible, likely or definitely related to study treatment at any time from the infusion until week 24, including infusion related toxicity and any toxicity possibly related to CAR-BCMA T cells.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Engraftment
Time Frame: 2 years
|
Duration of in vivo survival of CAR-BCMA T cells is defined as "engraftment".
The primary engraftment endpoint is the number of CAR-BCMA DNA vector copies per mL blood of CAR-BCMA T cells at regular intervals from 24 hours after initial infusion through 2 years of last infusion.
PCR for CAR-BCMA T vector sequences will be performed until any 2 sequential tests are negative, documented as engraftment of CAR-BCMA T cells.
|
2 years
|
Anti-tumor response of CAR-BCMA T cell infusion
Time Frame: 2 years
|
Observe the anti-tumor response of CAR-BCMA T cells to refractory or relapsed multiple myeloma (evaluated by diagnostic criteria International Myeloma Working Group (IMWG2014 version) as CR, sCR, ICR, MCR or VGPR).
|
2 years
|
Statistical parameter of efficacy assessment#PFS
Time Frame: 5 years
|
Statistical parameter#Progression-free Survival (PFS)
|
5 years
|
Statistical parameter of efficacy assessment#DCR
Time Frame: 2 years
|
Statistical parameter:Disease Control Rate (DCR)
|
2 years
|
Statistical parameter of efficacy assessment#ORR
Time Frame: 2 years
|
Statistical parameter:Objective Remission Rate (ORR)
|
2 years
|
Statistical parameter of efficacy assessment#OS
Time Frame: 5 years
|
Statistical parameter:Overall survival (OS)
|
5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of DNA copies of CAR-BCMA T cells in tissue samples
Time Frame: 2 years
|
The number of DNA copies of CAR-BCMA T cells in lymph node samples or bone marrow samples at regular intervals from 24 hours after the initial infusion.
|
2 years
|
Anti-drug antibody
Time Frame: 2 years
|
Detect titer of anti-BCMA anti-drug antibody (ADA).
|
2 years
|
Changes of cell subsets of CAR-BCMA T cells against T cells
Time Frame: 2 years
|
Observe the changes of cell subsets of CAR-BCMA T cells against T cells (Tcm, central memory T lymphocytes; Tem, effector memory T lymphocytes; Treg, regulatory T lymphocytes).
|
2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Siguo Hao, MD, Xin Hua Hospital of Shanghai Jiao Tong University of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
Other Study ID Numbers
- XH-17-018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory or Relapsed Multiple Myeloma
-
BeBetter Med IncCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Non-Hodgkin's LymphomaChina
-
AmgenActive, not recruitingRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid LeukemiaUnited States, Australia, Japan, Germany, Canada
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed or Refractory Chronic Lymphocytic LeukemiaUnited Kingdom, Spain, France, Australia
-
Oncopeptides ABTerminatedRelapsed Multiple Myeloma | Relapsed-Refractory Multiple MyelomaSerbia, Greece, Russian Federation, Czechia, Bulgaria, Georgia, Norway, Poland, Spain, Ukraine, Germany
-
Novartis PharmaceuticalsCompletedRefractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple MyelomaUnited States
-
Oncopeptides ABTerminatedRelapsed and/or Relapsed-refractory Multiple MyelomaUnited States, Netherlands, Denmark, Sweden, Italy
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States
-
University of LeedsCompletedRelapsed or Refractory Multiple MyelomaUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterExelixisCompletedRelapsed or Refractory Multiple MyelomaUnited States
-
Janssen Research & Development, LLCRecruitingRelapsed or Refractory Multiple MyelomaKorea, Republic of, Italy, Israel, Belgium, Denmark, Sweden, Canada, Spain, Czechia, France, Poland, Australia, Netherlands, United Kingdom, India
Clinical Trials on CAR-BCMA T cells
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingRefractory Multiple Myeloma | Relapse Multiple MyelomaChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingVasculitis | Amyloidosis | Autoimmune Hemolytic Anemia | POEMS SyndromeChina
-
Southwest Hospital, ChinaUnknownLymphoma | Leukemia | Multiple MyelomaChina
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingRefractory Multiple Myeloma | Relapse Multiple MyelomaChina
-
Chongqing Precision Biotech Co., LtdRecruitingMultiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma CellChina
-
Shenzhen University General HospitalRecruitingMultiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple MyelomaChina
-
Chongqing Precision Biotech Co., LtdRecruitingMultiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma CellChina
-
The First Affiliated Hospital of Nanchang UniversityUnknownRelapsed or Refractory Multiple MyelomaChina